Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996969 | 1.00 | ADRB3 (0.33) | ADRB3ADRA2BADRA2CCYP3A4ALDH1A1 | |
| SCHEMBL13502618 | 1.00 | ADRB3 (0.33) | ADRB3ADRA2BADRA2CCYP3A4ALDH1A1 | |
| SCHEMBL13502619 | 0.92 | ADRB3 (0.38) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL3528216 | 0.92 | ADRB3 (0.38) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL3528221 | 0.92 | ADRB3 (0.38) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL4166428 | 0.92 | ADRB3 (0.33) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL995273 | 0.88 | ALDH1A1 (0.34) | ADRB3ADRA2BADRA2CALDH1A1L3MBTL1 | |
| SCHEMBL995274 | 0.88 | ALDH1A1 (0.34) | ADRB3ADRA2BADRA2CALDH1A1L3MBTL1 | |
| SCHEMBL8249055 | 0.88 | ALDH1A1 (0.34) | ADRB3ADRA2BADRA2CALDH1A1L3MBTL1 | |
| SCHEMBL995888 | 0.87 | ALDH1A1 (0.36) | ADRB3ADRA2BADRA2CALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919898-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-26 | — | — | EP | disclosed |
| US-7666834-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-02-23 | — | — | US | disclosed |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HCCS, CBR1, CYP2B6 | ADRB3 2043/4885ADRA2B 3242/4885ADRA2C 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.